ArticleInfectious diseases and therapy2026
Burden of Respiratory Syncytial Virus in Older ADults in Nagasaki, Japan (Nagasaki ROAD): Preliminary Results (April 2024-March 2025) of a Prospective, Multicenter, Epidemiological Study.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOlder adults (OAs) and individuals with underlying comorbidities are at increased risk for severe respiratory syncytial virus (RSV) disease (e.g., lower respiratory tract disease [LRTD]) and related adverse outcomes. However, RSV is underdiagnosed and underestimated in OAs, posing a growing concern in super-aged societies like Japan.
methodsThis prospective, multicenter, epidemiological study (Nagasaki ROAD) aimed to enroll approximately 2700 participants aged ≥ 50 years with acute respiratory infection (ARI) seeking care at outpatient/emergency/inpatient settings at 15 medical institutions/hospitals/clinics in Nagasaki and its surroundings. Enrolled participants were followed for 180 days. RSV positivity in nasopharyngeal swab samples, detected by reverse transcription polymerase chain reaction, served as the primary diagnosis of RSV-related ARI/LRTD (RSV-ARI/LRTD). Hospital-wide and non-hospital-wide screening were adopted based on site-level operational realities and clinical workflows.
resultsData at enrollment (baseline/day 1) were analyzed from 1056 participants who were recruited between April 1, 2024 and March 31, 2025. The approximate positivity rate of RSV-ARI was 5.0% (n = 53), peaking from June to September 2024. The approximate positivity rate of SARS-CoV-2-ARI was 25.4% (n = 268), and influenza-ARI was 19.6% (n = 207). Hospitalization at or within 7 days of day 1 was observed in 20.8% (n = 11) of participants with RSV-ARI, 13.1% (n = 35) with SARS-CoV-2-ARI, and 13.0% (n = 27) with influenza-ARI. The most common comorbidities-of-interest were asthma (17.0% [n = 9]), chronic obstructive pulmonary disease (15.1% [n = 8]), and type 2 diabetes mellitus (7.5% [n = 4]) in participants with RSV-ARI. The observed need for oxygen supplementation was higher in participants with RSV-ARI (13.2% [n = 7]) than with SARS-CoV-2-ARI (3.4% [n = 9]) or influenza-ARI (8.7% [n = 18]).
conclusionsThese year 1 results contextualize the RSV disease burden in OAs aged ≥ 50 years in Nagasaki, Japan, providing an important basis for understanding RSV in Japanese OAs; findings complement existing evidence. Future analyses of all clinical outcomes through 180-day follow-up could further inform targeted prevention strategies in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.